Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma

Rechner, Laura Ann; Maraldo, Maja Vestmø; Vogelius, Ivan Richter; Zhu, Xiaorong Ronald; Brodin, Nils Patrik; Petersen, Peter Meidahl; Specht, Lena; Aznar, Marianne Camille

Published in:
Radiotherapy & Oncology

DOI:
10.1016/j.radonc.2017.07.033

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Proton therapy in Hodgkin lymphoma

Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold

Laura Ann Rechner a,b,⇑, Maja Vestmø Maraldo a, Ivan Richter Vogelius a, Xiaorong Ronald Zhu c, Bouthaina Shbib Dabaja d, Nils Patrik Brodin e, Peter Meidahl Petersen a, Lena Specht a, Marianne Camille Aznar b,f

a Department of Oncology, Rigshospitalet, University of Copenhagen; b Niels Bohr Institute, University of Copenhagen; c Department of Radiation Physics, The University of Texas MD Anderson Cancer Center; d Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center; e Institute for Onco-Physics, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, USA; f Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

ABSTRACT

Background and purpose: Due to the long life expectancy after treatment, the risk of late effects after radiotherapy (RT) is of particular importance for patients with Hodgkin lymphoma (HL). Both deep inspiration breath hold (DIBH) and proton therapy have been shown to reduce the dose to normal tissues for mediastinal HL, but the impact of these techniques in combination is unknown. The purpose of this study was to compare the life years lost (LYL) attributable to late effects after RT for mediastinal HL using intensity modulated radiation therapy (IMRT) in free breathing (FB) and DIBH, and proton therapy in FB and DIBH.

Materials and methods: Plans for each technique were created for 22 patients with HL. Doses were extracted and the risk of late effects and LYL were estimated.

Results: We found that the use of DIBH, proton therapy, and the combination significantly reduced the LYL compared to IMRT in FB. The lowest LYL was found for proton therapy in DIBH. However, when IMRT in DIBH was compared to proton therapy in FB, no significant difference was found.

Conclusions: Patient-specific plan comparisons should be used to select the optimal technique when comparing IMRT in DIBH and proton therapy in FB.

The majority of patients diagnosed with Hodgkin lymphoma (HL) have a long life expectancy following treatment. HL accounts for 12% of cancers in the 15–29-year age group [1], and treatment is highly effective with a 5-year relative survival rate of 93.1% for regional disease [2]. Consequently, HL survivors have a long time span in which they are at risk of developing late effects of treatment such as second cancers and cardiovascular disease [3], and it has been shown that RT contributes to that risk [4–6]. Therefore, it is important to minimize these risks for HL patients whenever possible.

Both deep inspiration breath hold (DIBH) and proton therapy have been shown to reduce the dose to normal tissues for HL patients with mediastinal disease [7–12]; however, to the authors’ knowledge, the impact of these techniques relative to each other or in combination has not been studied. An understanding of which of these has the largest impact on the risk of late effects would enable clinicians to prioritize between techniques, especially if the combination is not available.

Dose-effect models based on epidemiological data can be employed to estimate the risk of late effects from modern treatments. While such models have large uncertainty, they can be used as a tool in the context of comparative analysis of different treatment options. Our group has developed a method of risk modeling that converts organ at risk (OAR) dose into an estimated life years lost (LYL) from various possible late effects [13]. In this way, the severity of different late effects can be placed on a common scale for direct comparison.

In this study, we propose to investigate and compare the LYL from late effects of RT for HL with mediastinal involvement using intensity modulated radiation therapy (IMRT) in free breathing (FB) and in DIBH, and proton therapy in FB and DIBH.

http://dx.doi.org/10.1016/j.radonc.2017.07.033
© 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 125 (2017) 41–47 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Material and methods

Patients

22 patients with early-stage HL were enrolled in a previous prospective protocol to investigate the benefits of DIBH, described elsewhere [12,14]. In summary, the study included pre-chemotherapy positron emission tomography/computed tomography (PET/CT) scans and planning CT scans both in FB and in DIBH. Contouring was completed on both the FB and DIBH scans to define the CTV by the involved node technique [15]. Treatment plans were created on both scans, and the patients were treated with photons in either FB or DIBH, whichever was more clinically appropriate for the patient. This protocol was approved by the regional ethics committee for Copenhagen H-D-2007-0069.

Treatment planning

For the present retrospective study, four treatment plans were generated for each patient: IMRT in FB, IMRT in DIBH, proton therapy in FB, and proton therapy in DIBH. The prescription dose was 30.6 Gy in 17 fractions to the initially involved volume following the International Lymphoma Radiation Oncology Group (ILROG) guidelines [15]. Proton therapy doses were in Gy (RBE) (relative biological equivalent) assuming an RBE of 1.1 for protons [16], and 1 for photons. All plans were created using the Eclipse treatment planning system (photons: AAA version 10, protons: PCS version 13, Varian Medical Systems, Palo Alto, USA; proton beam data from Skandionkliniken, Uppsala, Sweden).

IMRT plans were created in accordance with the clinical procedure at Righospitalet, Copenhagen, Denmark [15]. For plans in FB, the CTV-to-PTV margins were 1.5 cm in the superior-inferior direction in the mediastinum, and 1 cm in other directions. For plans in DIBH, the CTV-to-PTV margins were 1 cm in all directions. The number of fields varied between 4 and 7, with 5 fields being the most common configuration. Whenever possible, fields were positioned to minimize entrance dose through the OARs (heart, lungs, and breasts). In general, 6 MV energy was used, with occasional use of 18 MV for supplementary fields.

Proton plans were created at Righospitalet with guidance from the experienced investigators at MD Anderson Cancer Center. Pencil beam scanning with an anterior-posterior and posterior-anterior beam arrangement was used for all patients. Beam-specific range uncertainties were calculated as 3.5% of the range to the distal edge of the CTV plus 3 mm. In cases where the beam-specific range uncertainties were less than the CTV-to-PTV margins used for IMRT planning, the same PTV was used as was used for IMRT planning (1.5 cm superior/inferior and 1 cm otherwise for FB and 1 cm for DIBH). For five patients, the range uncertainties for the posterior beam calculated with the formula above were 1–2 mm greater than the CTV-to-PTV margins that were used for IMRT planning in the anterior direction. For these patients, the PTV was expanded an additional 1–2 mm in the anterior direction to encompass the range uncertainty. For most patients, single-field optimization was used. For five patients with involved nodes surrounding the heart, multi-field optimization (intensity modulated proton therapy (IMPT)) was used to reduce dose to the heart.

During treatment planning for both IMRT and proton plans, the clinical priorities in order of highest to lowest were 1) target coverage, 2) reduction of the mean dose to the heart and lungs, and 3) reduction of the mean dose to the breasts (females). Additional objectives were used during optimization as needed for each patient to reduce the dose to normal tissues as much as possible.

Dosimetric analysis

Dosimetric data for the target and OARs were extracted for all plans. Specifically, the conformity index (CI; volume of body receiving 95% of prescription dose divided by volume of the PTV) and homogeneity index (HI; maximum dose in the PTV divided by the prescription dose) for the PTV were extracted as a measure of coverage of the target. The mean dose was extracted for the heart, heart valves, left anterior descending coronary artery (LADCA), lungs, and breasts (females). For proton plans, neutron doses were added to the therapeutic doses using measured data by Schneider et al. 2002 following the methods of Cella et al. 2013. 6 × 10⁻¹⁴ Sv/proton and 10¹³ protons per Gy (RBE) of therapeutic dose were assumed [17,18]. This corresponds to the neutron dose equivalent in the region of the target, but it was applied to the OARs since all OARs considered in this study were adjacent to or overlapping with the target. Cumulative dose-volume histograms (DVHs) were exported for the heart and lung, neutron dose added to the proton plans, and mean DVHs for all patients for each treatment technique were calculated.

To estimate the effect of uncertainties in positioning and CT calibration on the dose, robustness analysis was performed by calculating the plan uncertainty doses using the built-in tool in the treatment planning system. A positioning uncertainty of 5 mm for both IMRT and proton therapy and Hounsfield Unit (HU) uncertainty of 3.5% for proton therapy were assumed. These uncertainty doses represent ‘worst case’ scenarios, not an estimation of the actual delivered dose.

Hazard ratios

Hazard ratios (HRs) per Gy relative to the unirradiated population were estimated from the literature for various late effects. The hazard ratios of heart failure [19], myocardial infarction [19], valvular heart disease [20], lung cancer [21], and breast cancer [22] (females) were estimated. Most risk models displayed a linear dose–response relationship and as such, the mean dose to the respective organ was used. An exception was valvular heart disease, where the equivalent dose in 2 Gy fractions (calculated from the differential DVH) to either the mitral valve or the aortic valve, whichever received the higher dose, was used in the risk calculation [20] (personal communication with Dr. Cutter). The risk models used are listed in Table S1.

Life years lost calculation

To convert doses to an estimation of the impact of the late effects on life expectancy after treatment, the LYL was calculated for each plan [13]. The LYL is the estimated reduction in life expectancy attributable to late effects from RT, and takes into account the age at exposure, the patient’s sex, and the prognosis of the possible late effects [23–25]. The endpoints included in the LYL were heart failure, myocardial infarction, valvular heart disease, lung cancer, and breast cancer (females). Calculations were performed in Matlab (version 2016b, The MathWorks, Inc, Natick, MA) using the risk models in Table S1 and the methodology and formulae in Brodin et al. [13] to integrate over attained age and account for mortality after an acquired late effect.

Statistical analysis

The Friedman test was used for the dosimetric and risk metrics, with post-hoc two-sided pairwise analysis using Bonferroni correction and p-values <0.05 were considered significant. All statistical analyses were performed in Matlab.
Results

Four plans were created for each patient, resulting in a total of 88 plans. Example treatment plans for each technique for a representative patient are shown in Fig. 1. Mean DVHs for the heart and lung are plotted in Figs. 2 and 3, the individual DVHs for each patient can be found in the supplementary material (Figs. S1 and S2). The HI and CI values were considered clinically equivalent for all plans (Table S2). All plans were considered to be robust with respect to positioning and range uncertainties (Table S3).

DIBH reduced the dose to cardiovascular structures compared to FB, regardless of whether proton therapy or IMRT was used (Table 1). This benefit was especially observed for the heart valves, where DIBH led to a median dose reduction of 4.7 Gy for IMRT and 2.3 Gy for proton therapy.

DIBH also reduced the mean dose to the lungs by 2.3 Gy for IMRT and 1.2 Gy for proton therapy, although the difference for proton therapy was not statistically significant. Nevertheless, the lowest mean dose to the lungs was found with proton therapy in DIBH, with a reduction of 4.6 Gy relative to IMRT in FB. Proton
therapy reduced the mean lung dose, but no statistically significant difference was observed between proton therapy in FB and IMRT in DIBH.

In contrast, a significant reduction in mean breast dose of about 3 Gy was found when proton therapy was used compared to IMRT, with or without DIBH.

As most of the risk models used in this study displayed linear dose–response relationships, HR followed the same trend as the mean dose measures (Table 2). The risk of breast cancer was significantly reduced using proton therapy in comparison to IMRT in DIBH. However, for lung cancer and heart-related risks, no statistically significant difference in HR was seen when proton therapy in FB or DIBH was compared to IMRT in DIBH.

When compared with IMRT in FB, the addition of DIBH and proton therapy, alone or in combination, significantly reduced the LYL, and the lowest LYL from treatment was found for proton therapy in DIBH. However, when proton therapy in FB was compared with IMRT in DIBH, and when proton therapy in DIBH was compared to proton therapy in FB, no significant differences in LYL were found.

The total LYL was either dominated by lung cancer or valvular heart disease for all patients, with the LYL from valvular heart disease being highly variable between patients and techniques. The median LYL (range) for all plans was 0.33 (0.03–1.07) years from lung cancer and 0.46 (0.002–5.35) years from valvular heart disease. The median dose (range) to the aortic or mitral valve was 26.8 (16.3–31.3) Gy for plans where valvular heart disease caused greater than 1 year of LYL. The details of the LYL by cause are shown in Table 2 for two representative patients (both had approximately median-sized PTVs of about 1000 cc (range: 123–1943 cc for all patients)). The LYL per technique per patient with 95% confidence intervals are shown in Figs. S9–S13.

**Discussion**

In this study, we investigated the impact of DIBH and proton therapy, individually and in combination, in a cohort of patients with mediastinal HL. Our study suggests that if only IMRT is available, IMRT in DIBH is superior to IMRT in FB with respect to the risk of late effects. If both IMRT and proton therapy are available in DIBH, our study suggests that proton therapy in DIBH is superior to IMRT in DIBH and FB. If DIBH is available to the patient in combination with IMRT but not with proton therapy, our study did not find any statistically significant difference in the LYL over the

<table>
<thead>
<tr>
<th>Metric</th>
<th>IMRT FB (1) (Mean, Median)</th>
<th>IMRT DIBH (2) (Mean, Median)</th>
<th>Proton FB (3) (Mean, Median)</th>
<th>Proton DIBH (4) (Mean, Median)</th>
<th>Proton DIBH (4) (Median of Pairwise Differences, Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Dose (Gy)</td>
<td>8.0 (8.0–14.4)</td>
<td>6.1 (6.0–13.6)</td>
<td>3.7 (3.7–7.4)</td>
<td>2.1 (2.0–5.4)</td>
<td>0.5 (0.4–14.4)</td>
</tr>
<tr>
<td>Valve Dose (Gy)</td>
<td>4.4 (4.4–9.0)</td>
<td>3.1 (3.1–7.0)</td>
<td>1.7 (1.7–3.4)</td>
<td>1.1 (1.1–3.4)</td>
<td>0.6 (0.5–13.8)</td>
</tr>
<tr>
<td>Valve Dose EQD2 (Gy)</td>
<td>3.4 (3.4–6.9)</td>
<td>2.4 (2.4–4.9)</td>
<td>1.5 (1.5–3.0)</td>
<td>0.9 (0.9–2.3)</td>
<td>0.3 (0.3–13.6)</td>
</tr>
<tr>
<td>LADCA Dose (Gy)</td>
<td>7.7 (7.7–14.9)</td>
<td>5.8 (5.8–12.9)</td>
<td>4.6 (4.6–11.8)</td>
<td>3.4 (3.4–8.6)</td>
<td>0.6 (0.6–13.6)</td>
</tr>
<tr>
<td>Lung Dose (Gy)</td>
<td>9.8 (9.8–25.6)</td>
<td>7.0 (7.0–14.4)</td>
<td>4.6 (4.6–12.4)</td>
<td>3.0 (3.0–8.6)</td>
<td>0.6 (0.6–14.0)</td>
</tr>
<tr>
<td>Breast Dose (Gy)</td>
<td>1.4 (1.4–28.8)</td>
<td>0.8 (0.8–14.2)</td>
<td>0.3 (0.3–4.8)</td>
<td>0.2 (0.2–4.8)</td>
<td>0.1 (0.1–10.1)</td>
</tr>
</tbody>
</table>
whole cohort between the two techniques and patient-specific comparative planning would be required to determine the optimal technique. Our study did not find a statistically significant difference when proton therapy in FB was compared with proton therapy in DIBH; however, proton therapy in DIBH did result in the lowest estimated LYL, and, unlike proton therapy in FB, a significant difference was seen when proton therapy in DIBH was compared to IMRT in DIBH.

An earlier study was reported by Cella et al. [18] comparing photon and proton techniques for a patient with HL, without considering DIBH. In their study, the relative risk (RR) of second cancers was estimated after mediastinal RT for conventional RT compared to various intensity modulated radiotherapies and proton therapy. They also found a reduction in both breast and lung cancer risk when proton therapy was compared to IMRT, similar to our results.

Toltz et al. [26] also found a reduced risk of breast and lung cancer for proton therapy in FB relative to IMRT in FB in the form of helical tomotherapy for mediastinal HL for 20 patients. However, unlike our study, they did not find a reduction in cardiac mortality between the two techniques. This could in part be due to differences in the choice risk model, which predicted very small excess absolute risks of cardiac toxicity (median of 0.05% for both tomotherapy and proton therapy) in their study.

One strength of the present study is that we have included the most advanced techniques available for this patient group. Plans were created using the involved node technique, contoured using pre-chemotherapy PET/CT acquired in the treatment position in both FB and DIBH, with and planned with pencil beam scanning for the proton plans. Furthermore, we compared different combinations of advanced treatment techniques, so the optimal solution can be selected depending on which techniques are available for the patient. Though DIBH is gaining acceptance in this patient

<table>
<thead>
<tr>
<th>Metric</th>
<th>IMRT FB (1)</th>
<th>Proton FB (3)</th>
<th>Proton DIBH (4)</th>
<th>Median of Pairwise Differences (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Failure HR</td>
<td>1.00–2.0</td>
<td>1.00–2.0</td>
<td>1.00–1.5</td>
<td>1.00–1.0 (0.01–1.5)</td>
</tr>
<tr>
<td>Mediastinal Ischemia HR</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5 (0.01–1.5)</td>
</tr>
<tr>
<td>Myocardial Ischemia HR</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5 (0.01–1.5)</td>
</tr>
<tr>
<td>Valvular Heart Disease HR</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5 (0.01–1.5)</td>
</tr>
<tr>
<td>Lung Cancer HR</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5 (0.01–1.5)</td>
</tr>
<tr>
<td>Breast Cancer HR</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5</td>
<td>1.00–1.5 (0.01–1.5)</td>
</tr>
<tr>
<td>Total LYL (years)</td>
<td>1.00–2.0</td>
<td>1.00–2.0</td>
<td>1.00–2.0</td>
<td>1.00–2.0 (0.01–2.0)</td>
</tr>
</tbody>
</table>

The Friedman test and post-hoc analysis with Bonferroni correction were used for pairwise comparisons. P-values <0.05 and <0.01 are marked with * and **, respectively. Doses are in Gy (RBE) for proton therapy. Breast cancer HR given for 14 female patients. A plot of total LYL can be found in the supplementary material (Fig. S8).
Late effects after protons/DIBH for HL

Conflicts of interest statement
Lauren Ann Rechner was partially funded by a grant from Varian Medical Systems for this project. Varian had no involvement in the study design or the writing of this manuscript. Laura also accepted a speaker fee from Varian in 2016 for an unrelated project.

Acknowledgements
The authors acknowledge Skandionkliniken, Uppsala, Sweden for providing their proton beam data. We would also like to acknowledge our colleagues Michael Lundemann Jensen, Line Bjerrregaard Stick, Jonas Scherman Rydhög, Manuel Oyervides, and David Cutter for their technical assistance and expert opinions. Nils Patrik Brodin acknowledges support from the NIH/National Center for Advancing Translational Science (NCATS) Einstein-Montefiore CTSI Grant Number KL2TR001071 and UL1TR001073. Marianne Camille Aznar acknowledges support from Cancer Research UK (grant number C8225/A21133).

Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.radonc.2017.07.033.

References


